McNeil Ltd

Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UG
Medical Information Direct Line: 01344 864042

Summary of Product Characteristics last updated on the eMC: 02/07/2009
SPC Non Drowsy Sudafed Children's Syrup


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

NON-DROWSY SUDAFED DECONGESTANT ELIXIR

NON-DROWSY SUDAFED CHILDREN'S SYRUP*


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

NON-DROWSY SUDAFED DECONGESTANT ELIXIR contains -

Pseudoephedrine Hydrochloride

30.0 mg per 5 ml

 

 


Go to top of the page
3. PHARMACEUTICAL FORM

Liquid for oral administration.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of nasal congestion and congestion of mucous membranes of the upper respiratory tract associated with the common cold.


Go to top of the page
4.2 Posology and method of administration

Oral

Adults and Children aged 12 years and over:

10 ml elixir every 4-6 hours up to 4 times a day.

Children 6 - 12 years

5 ml elixir every 4-6 hours up to 4 times a day. Not to be used for more than five days without the advice of a doctor. Parents or carers should seek medical attention if the child's condition deteriorates during treatment.

NON-DROWSY SUDAFED DECONGESTANT ELIXIR may be diluted 1:1 (1 in 2) or 1:3 (1 in 4) with syrup BP. These dilutions are stable for 4 weeks if stored at 25°C.

Children under 6 years

NON-DROWSY SUDAFED DECONGESTANT ELIXIR is contraindicated in children under the age of 6 years (see section 4.3).

Use in the Elderly

There have been no specific studies of NON-DROWSY SUDAFED DECONGESTANT ELIXIR in the elderly, experience has indicated that normal adult dosage is appropriate.

Hepatic Dysfunction

Caution should be exercised when administering NON-DROWSY SUDAFED DECONGESTANT ELIXIR to patients with severe hepatic impairment.

Renal Dysfunction

Caution should be exercised when administering NON-DROWSY SUDAFED DECONGESTANT ELIXIR to patients with moderate to severe renal impairment.

Do not exceed the stated dose.

Keep out of the reach and sight of children.


Go to top of the page
4.3 Contraindications

NON-DROWSY SUDAFED DECONGESTANT ELIXIR is contraindicated in individuals with known hypersensitivity to the product or any of its components.

Concomitant use of other sympathomimetic decongestants, beta-blockers (see section 4.5) and monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOI treatment (see section 4.5)

Cardiovascular disease including hypertension

Diabetes mellitus

Phaeochromocytoma

Hyperthyroidism

Closed angle glaucoma

Severe renal impairment

Not to be used in children under the age of 6 years.


Go to top of the page
4.4 Special warnings and precautions for use

Use with caution in occlusive vascular disease

If any of the following occur, NON-DROWSY SUDAFED DECONGESTANT ELIXIR should be stopped

• Hallucinations

• Restlessness

• Sleep disturbances

Caution in moderate renal impairment


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

• MAOIs and/or RIMAs: Should not be given to patients taking MAOIs or within 14 days of stopping treatment: increased risk of hypertensive crisis

• Moclobemide: risk of hypertensive crisis.

• Antihypertensives (including adrenergic neurone blockers & beta-blockers): NON-DROWSY SUDAFED DECONGESTANT ELIXIR may block the hypotensive effects.

• Cardiac glycosides: increased risk of dysrhythmias

• Ergot alkaloids (ergotamine & methysergide): increased risk of ergotism

• Appetite suppressants and amphetamine-like psychostimulants: risk of hypertension

• Oxytocin – risk of hypertension

• Enhances effects of anticholinergic drugs (such as TCAs)


Go to top of the page
4.6 Pregnancy and lactation

Although pseudoephedrine has been in widespread use for many years without apparent ill consequence, there are no specific data on its use during pregnancy. Caution should therefore be exercised by balancing the potential benefit of treatment to the mother against any possible hazards to the developing foetus.

Systemic administration of pseudoephedrine, up to 50 times the human daily dose in rats and up to 35 times the human daily dosage in rabbits did not produce teratogenic effects. Pseudoephedrine is excreted in breast milk in small amounts, but the effect of this on breast-fed infants is not known. It has been estimated that 0.5 - 0.7% of a single dose of pseudoephedrine ingested by a mother will be excreted in the breast milk over 24 hours.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Cardiovascular effects

• Tachycardia/palpitations

• Other cardiac dysrhythmias and hypertension

CNS effects

• Irritability

• Anxiety

• Restlessness

• Excitability

• Insomnia

• Hallucinations and paranoid delusion

Skin reactions including rash

Hypersensitivity reactions – cross-sensitivity may occur with other sympathomimetics.

Other reactions

• Nausea and/or vomiting

• Headache

• Urinary retention


Go to top of the page
4.9 Overdose

As with other sympathomimetic agents, symptoms of overdose include irritability, restlessness, tremor, convulsions, palpitations, hypertension and difficulty in micturition.

Necessary measures should be taken to maintain and support respiration and control convulsions. Gastric lavage should be performed if indicated. Catheterisation of the bladder may be necessary. If desired, the elimination of pseudoephedrine can be accelerated by acid diuresis or by dialysis.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Psuedoephedrine has direct and indirect sympathlomimetic activity and is an orally effective upper respiratory tract decongestant. Psuedoephedrine is substantially less potent than ephedrine in producing both tachycardia and elevation in systolic blood pressure and considerably less potent in causing stimulation of the central nervous system.


Go to top of the page
5.2 Pharmacokinetic properties

Pseudoephedrine is rapidly and completely absorbed after oral administration. After an oral dose of 180 mg to man, peak plasma concentrations of 500-900 ng/ml were obtained about 2 hours post dose. The plasma half life was about 5.5 hours and was increased in subjects with alkaline urine and decreased in subjects with acid urine. The only metabolism was n-demethylation which occurred to a small extent. Excretion was mainly via the urine.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Citric Acid Monohydrate

Sucrose

Glycerol

Methyl Hydroxybenzoate

Sodium Benzoate

Ponceau 4R, E124

Flavour, Raspberry Essence No 1NA

Purified Water


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

36 months unopened


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.

Protect from light.


Go to top of the page
6.5 Nature and contents of container

30 ml and *100 ml amber glass bottles with metal roll on closures or plastic screw caps, each cap containing a PVDC-lined wad or polyethylene/expanded polyethylene laminated wad.

Amber glass bottles with a 3 piece plastic child resistant, tamper evident closure fitted with a polyvinylidene chloride (PVDC) faced wad or polyethylene/expanded polyethylene laminated wad.

The 30 ml bottle is a sample pack.

*A spoon with a 5 ml and a 2.5 ml measure is supplied with this pack.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

McNeil Products Limited

Foundation Park

Roxborough Way

Maidenhead

Berkshire SL6 3UG

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 15513/0023


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

28 March 1997


Go to top of the page
10. DATE OF REVISION OF THE TEXT

31 March 2009

* Non-Drowsy Sudafed Decongestant Elixir is an alternative name for this product. Please read Non-Drowsy Sudafed Children's Syrup as an alternative where Non-Drowsy Sudafed Decongestant Elixir appears.



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/19570/SPC/Non Drowsy Sudafed Children's Syrup/

Active Ingredients/Generics

 
   pseudoephedrine hydrochloride


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk